Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGNOSTOS trial of nab-paclitaxel doublets in first-line cancer of unknown primary
2014-005018-47Phase 2Completed
- Sponsor
- Fondazione del Piemonte per l'Oncologia
- Start
- Dec 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in cancer of unknown primary (CUP) comparing Abraxane + carboplatin with Abraxane + gemcitabine (2 arms). Primary endpoint: Objective response rate. Started Dec 2020; status: completed.
02
Drugs
nab-paclitaxelcarboplatingemcitabine
03
Conditions
cancer of unknown primary (CUP)
Beyond the preview
Go deeper on 2014-005018-47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005018-47.